A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...

Cornell researchers have confirmed that a previously identified biomarker for detecting the presence of malignant testicular germ cell tumors has the potential to improve patient outcomes through ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...

TransCode Therapeutics (RNAZ) announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose.

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 24th Annual ...

Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal ...

The origin of their recognition comes from a pair of studies published in the journal Cell way back in 1993, which demonstrated for the first time that microRNA was involved in gene regulation in ...